NETRF Welcomes New Members to its Board of Scientific Advisors

The Neuroendocrine Tumor Research Foundation (NETRF) welcomes five new members to its Board of Scientific Advisors (BOSA), a volunteer council of highly distinguished medical and research leaders who share NETRF’s commitment to advancing the understanding, diagnosis, and treatment of neuroendocrine cancer.

“The new NET experts joining BOSA in 2020 increase the diversity of experience on our scientific advisory board,” said John Kanki, PhD, NETRF Director of Research. “We now have greater representation of translational researchers and are excited to add a member with extensive experience in lung NETs.”

2020 appointments to the NETRF Board of Scientific Advisors:

Bradley E. Bernstein, MD, PhD 

Harvard Medical School, Massachusetts General Hospital

James A. Bibb, PhD

University of Alabama at Birmingham Medical Center

Guillermina (Gigi) Lozano, PhD

University of Texas MD Anderson Cancer Center

John D. Minna, MD

University of Texas (UT) Southwestern Medical Center

Dawn E. Quelle, PhD

Holden Comprehensive Cancer Center, University of Iowa College of Medicine

The BOSA is central to the rigorous scientific review that allows NETRF to quickly identify the most promising grant applications and fund projects that have the most potential to transform the NET landscape.  In addition, the BOSA provides leadership for and participation in the annual NETRF Research Symposium.

All members of the NETRF Board of Scientific Advisors are recognized experts in medical research, published authors in the top peer-reviewed medical journals, and principal investigators of collaborative research projects at top-ranked universities and institutes.